$SLS Celator’s ( Bought for $1.5B ) lead drug candidate is a combination of cytarabine and daunorubicin (Vyxeos, known as CPX-351). From the Article The company said in March that patients on its drug with high-risk secondary acute myeloid leukemia lived a median time of 9.56 months—meaning half lived longer, and half didn’t live that long. That median survival time compared with 5.95 months for patients who were randomly assigned to get the standard treatment with cytarabine and daunorubicin. Compare to SLS Results: In February 2020, SELLAS announced positive follow-up data from its Phase 1/2 study of GPS in CR2 AML patients. The final data show a median overall survival (OS) of 21.0 months, at a median follow-up of 30.8 months, in patients receiving GPS compared to 5.4 months in patients treated with best standard care (p-value < 0.02). In January 2020, SELLAS announced that it commenced patient screening for its pivotal Phase 3 REGAL study of GPS in patients with AML in CR2.